Complementary therapy to target LDL cholesterol: The role of the ezetimibe/simvastatin combination

Vascular Health and Risk Management

Volumn 2, Issue 1, 2006, Pages 31-38

  Neal, Ryan C ^a,b   Jones, Peter H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Center for Cardiovascular Development   (United States)

Author keywords

Combination lipid treatment; Ezetimibe; Statin

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; COLESTYRAMINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET THERAPY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME INHIBITION; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG COMBINATIONS; HUMANS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 33646029692     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.1.31     Document Type: Review

References (33)

1. [ACE] American College of Endocrinology. 2002. Consensus statement on guidelines for glycemic control. Endocr Pract, 8(Suppl):6-11.
2. [AHA] American Heart Association. 2002. Heart disease and stroke statistical update. Dallas, TX: AHA: 2001.
3. [AHA] American Heart Association. 2004. Heart disease and stroke statistics - 2004 update. Dallas, TX: AHA; 2003:11.
4. [ALLHAT] ALLHAT Officers and Coordinators for the ALLHAT Collaborative Group. 2000. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 283: 1967-75.
5. Altmann SW, Davis HR, Zhu L, et al. 2004. Neimann-PickC1 like 1 protein is critical for intestinal cholesterol absorption. Science, 303:1201-4.
6. Ballantyne CM, Abase N, Yuan Z, et al. 2005. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J, 149:464-73.
7. Ballantyne CM, Blazing MA, King TR, et al. 2004. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol, 93:1487-94.
8. Ballantyne CM, O'Keefe JH, Gotto GM. 2005. Overview of dyslipidemia. dyslipidemia essentials. 2ng Ed. Physician Pr. p 1-8.
9. Beckman JA, Creager MA, Libby P, et al. 2002. Diabetes and atherosclerosis epidemiology, pathophysiology, and management. JAMA, 287:2570-81.
10. Brown BG, Brockenbrough A, Zhao XQ, et al. 1998. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up. Circulation, 98(Suppl I):1-635.
11. Brown BG, Zhao XQ, Chait A, et al. 2001. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary artery disease. N Engl J Med, 345:1583-92.
12. Buchwald H, Varco RL, Matts JP, et al. 1990. Effect of partial ileal bypass surgery on mortality and morbidity of coronary heart disease in patients with hyperlipidemia. Report of the Program on Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med, 323:946-55.
13. Cannon CP, Braunwald E, McCabe CM, et al. 2004. Intensive versus moderate lipid lowering statins after acute coronary syndromes. (PROVE-IT) N Engl J Med, 380:1495-504.
14. [CDCP] Centers for Disease Control and Prevention, 2004. Morbidity Weekly Report. MMWR, 53:4-7.
15. Chobanian AV, Bakin GL, Black HR, et al. 2003. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 Report. JAMA, 289: 2560-72.
16. Colhoun HM, Betteridge DJ, Durrington PN, et al. 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS); multicentre randomized placebo-controlled trial. Lancet, 364:685-96.
17. de Lorgeril M, Salen P, Martin JL, et al. 1999. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complication after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation, 99:779-85.
18. Goldberg AC, Sapre A, Lin J, et al. 2004. Efficacy and safety of ezetimibe coadministration with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc, 79:620-30.
19. Grundy SM, Cleeman JI, Merz B, et al. 2004. Implications of recent clinical for the national cholesterol education program Adult Treatment Panel III guidelines. Circulation, 93:193-5.
20. [HPS] Heart Protection Study Collaborative Study. 2002. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomized placebo-controlled trial. Lancet, 360:7-22.
21. Jones PH, Davidson MH, Stein EA, et al. 2003. Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR*) Trial. Am J Cardiol, 92: 152-60.
22. Kashyap ML, McGovern ME, Berra K, et al. 2002. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol, 89:672-8.
23. Knopp RH, Dujovne CA, Le Beaut A, et al. 2003. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolemia: a pooled analysis from two Phase III clinical studies. Int J Clin Proct, 57:363-8.
24. LaRosa JC, Grundy SM, Waters DD, et al 2005. The treating to new targets investigators. N Engl J Med, 352:1425-35.
25. [LRC] The Lipid Research Clinics-Coronary Primary Prevention Trial Investigators. The relationship of incidence of coronary heart disease to cholesterol lowering. 1984. JAMA, 251:351-64.
26. Morbidity and Mortality: 2002 Chart book on cardiovascular, lung, and blood diseases. NIH.
27. [NCEP] National Cholesterol Education Program. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP): expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III). JAMA, 285:2486-97.
28. [NHANES] National Health and Nutrition Examination Survey. 1999. Third National Health and Nutrition Examination (NHANES III 1988-1994) [online]. Accessed 12 May 2005. URL: http://www.cdc.gov/nchs/nhanes.htm.
29. Pearson TP, Denke MA, McBride PE, et al. 2005. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin Effectiveness (EASE) trial. Mayo Clin Proc, 80:587-95.
30. Sager PT, Capece R, Lipka L, et al. 2005. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis, 179:361-7.
31. Sever PS, Dahlof B, Poulter NR et al. 2003. The Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet, 361:1149-58.
32. Shepherd J, Bloun GJ, Murphy MB et al. 2002. Prospective Study of Pravastatin in the Elderly at Risk. (PROSPER). Lancet, 360: 1623-30.
33. Van Heek M, Farley C, Compton DS, et al. 2000. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmocol, 129:1748-54.